P53 expression, DNA ploidy and mitotic index as prognostic factors in patients with epithelial ovarian carcinoma

Tumori

Volumn 90, Issue 6, 2004, Pages 600-606

  Ceccaroni, Marcello ^a   Chieco, Pasquale ^a   Alboni, Carlo ^a   De Iaco, Pierandrea ^a   Pagano, Katia ^a   Ceccarelli, Claudio ^a   Santini, Donatella ^a   Taroni, Beatrice ^a   Pelusi, Giuseppe ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Genomic instability; Human; Mitotic index; Ovarian carcinoma; P53; Ploidy; Proliferation; Survival

Indexed keywords

PROTEIN P53; TOLONIUM CHLORIDE;

ADULT; AGED; ARTICLE; CANCER STAGING; CELL PROLIFERATION; FEMALE; FEULGEN STAINING; GENE OVEREXPRESSION; GENOMIC INSTABILITY; HUMAN; HUMAN TISSUE; IMAGE CYTOMETRY; IMMUNOHISTOCHEMISTRY; LOW MALIGNANT POTENTIAL TUMOR; MAJOR CLINICAL STUDY; MITOSIS INDEX; OVARY CARCINOMA; PLOIDY; PROGNOSIS; SURVIVAL RATE; TUMOR; TUMOR SUPPRESSOR GENE;

EID: 14244259710     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160409000612     Document Type: Article

References (57)

1. Moss C, Kaye SB: Ovarian cancer: progress and continuing controversies in management. Eur J Cancer, 38: 1701-1707, 2002.
2. Kristensen GB, Tropé C: Epithelial ovarian carcinoma. Lancet, 349: 113-117, 1997.
3. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ: American Cancer Society. Cancer statistics. CA Cancer J Clin, 54: 8-29, 2004.
4. Bast RC Jr: Status of tumor markers in ovarian cancer screening. J Clin Oncol, 21 (Suppl 10): 200-205, 2003.
5. Perez RP, Godwin AK, Hamilton TC, Ozols RF: Ovarian cancer biology. Sem Oncol, 18: 186-204, 1991.
6. Marx D, Meden H, Brune T, Kron M, Korabiowska M, Kuhn W, Schauer A: Mib-1 evaluated proliferative activity in ovarian cancer with respect to prognostic significance. Anticancer Res, 17: 775-780, 1997.
7. Braly P: DNA content and S-phase fraction in epithelial ovarian cancer: what information do they really add? Gynecol Oncol, 71: 1-2, 1998.
8. Matias-Guiu X, Prat J: Molecular pathology of ovarian carcinomas. Virchows Arch, 433: 103-111, 1998.
9. International Federation of Gynecology and Obstetrics: Changes in definition of clinical staging for carcinoma of the cervix and the ovary. Am J Obstet Gynecol, 56: 263-264, 1987.
10. Faccioli S, Cavicchi O, Caliceti U, Rinaldi Ceroni A, Chieco P: Cell proliferation as an independent predictor of survival for patients with advanced nasopharyngeal carcinoma. Mod Pathol, 10: 884-894, 1997.
11. Ceccarelli C, Santini D, Chieco P, Taffurelli M, Gamberini M, Pileri S, Marrano D: Retinoblastoma (RB1) gene product expression in breast carcinoma. Correlation with Ki-67 growth fraction and biopathological profile. J Clin Pathol, 51: 818-824, 1998.
12. Chieco P, Pagnoni M, Romagnoli E, Melchiorri C: A rapid and simple staining method, using toluidine blue, for analysing mitotic figures in tissue sections. Histochem J, 25: 569-577, 1993.
13. Melchiorri C, Bolondi L, Chieco P, Pagnoni M, Gramantieri L, Barbara L: Diagnostic and prognostic value of DNA ploidy and cell nuclearity in ultrasound-guided liver biopsies. Cancer, 74: 1713-1719, 1994.
14. Chieco P, Jonker A, Van Noorden CJF: Image cytometry. BIOS Scientific Publishers, Oxford, 2001.
15. Chieco P, Melchiorri C, Lisignoli G, Marabini A, Orlandi: A multifaced DNA ploidy analysis to determine ovarian carcinoma aggressiveness. Cancer, 67: 1878-1885, 1991.
16. Kaplan EL, Meier P: Nonparametric estimation for incomplete observations. J Am Statist Assoc, 53: 457-481, 1958.
17. Lee ET: Statistical methods for survival data analysis. John Wiley, New York, 1992.
18. Altman DG, De Stavola BL, Love SB, Stepniewska KA: Review of survival analyses published in cancer journals. Br J Cancer, 72: 511-518, 1995.
19. Cox DR: Regression models and life tables (with discussion). J R Statist Soc, B3: 197-220, 1972.
20. Cook RD: Detection of influential observations in linear regression. Technometrics, 19: 15-18, 1977.
21. Nicolson GL: Tumor cell instability, diversification and progression to the metastatic phenotype: from oncogene to oncofetal expression. Cancer Res, 47: 1473-1487, 1987.
22. Nowell PC: Mechanisms of tumor progression. Cancer Res, 46: 2203-2207, 1986.
23. Nowell PC: Chromosomes and cancer: the evolution of an idea. Adv Cancer Res, 62: 1-18, 1993.
24. Mitelman: Catalog of chromosomal aberrations in cancer. Wiley-Liss, New York, 1994.
25. Duesberg P, Rausch C, Rasnik D, Hehlmann R: Genetic instability of cancer cells is proportional to their degree of aneuploidy. Proc Natl Acad Sci (USA), 95: 13692-13697, 1998.
26. Sieber OM, Heinimann K, Tomlinson IP: Genomic instability: the engine of tumorigenesis? Nat Rev Cancer, 3: 701-708, 2003.
27. Weinberg RA: Oncogenes, antioncogenes, and the molecular bases of multistep carcinogenesis. Cancer Res, 49: 3713-3721, 1989.
28. Kaufmann WK, Kaufmann DG: Cell cycle control, DNA repair and initiation of carcinogenesis. FASEB J, 7: 188-191, 1993.
29. Teneriello MG, Ebina M, Linnoila RI, Henry M, Nash JD, Park RC, Birrer MJ: p53 and Ki-ras gene mutations in epithelial ovarian neoplasms. Cancer Res, 53: 3103-3108, 1993.
30. Kupryjanczyk J, Bell DA, Dimeo D, Beauchamp R, Thor AD, Yandell DW: P53 gene analysis of ovarian borderline tumors and stage I carcinomas. Hum Pathol, 27: 387-392, 1995.
31. Haapasalo H, Collan Y, Atkin NB, Pesonen E, Seppä A: Prognosis of ovarian carcinomas: prediction by histoquantitative methods. Histopathology, 15: 167-178, 1989.
32. Coley HM, Sargent JM, Titley J, Taylor CG: Lack of prognostic significance of ploidy and S-phase measurements in advanced ovarian cancer. Anticancer Res, 19: 2111-2116, 1999.
33. Nagai N, Oshita T, Fujii T, Katsube Y, Matsubayashi S, Ohama K: Are DNA ploidy and epidermal growth factor receptor prognostic factors for untreated ovarian cancer? A prospective study. Am J Clin Oncol, 24: 215-221, 2001.
34. Meyer JS, Gersell DJ, Yim S: Cell proliferation in ovarian carcinoma: superior accuracy of S-phase fraction (SPF) by DNA labeling index versus flow cytometric SPF, lack of independent prognostic power for SPF and DNA ploidy, and limited effect of SPF on tumor growth rate. Gynecol Oncol, 81: 466-476, 2001.
35. Kimmig R, Wimberger P, Hillemanns P, Kapsner T, Caspari C, Hepp H: Multivariate analysis of the prognostic significance of DNA-ploidy and S-phase fraction in ovarian cancer determined by flow cytometry following detection of cytokeratin-labeled tumor cells. Gynecol Oncol, 84: 21-31, 2002.
36. Itamochi H, Kigawa J, Sugiyama T, Kikuchi Y, Suzuki M, Terakawa N: Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary. Obstet Gynecol, 100: 281-287, 2002.
37. Miliaras D: Volume-corrected mitotic index and P53 immunoreactivity in borderline and malignant epithelial ovarian tumors. Anal Quant Cytol Histol, 21: 425-429, 1999.
38. Schmitt FC, Soares R, Cirnes L, Seruca R: P53 in breast carcinomas: association between the presence of mutation and immunohistochemical expression using a semiquantitative approach. Pathol Res Pract, 194: 815-819, 1998.
39. Darnton SJ: Demystified... p53. Mol Pathol, 51: 248-253, 1998.
40. DiCioccio RA, Werness BA, Peng R, Allen HJ, Piver MS: Correlation of TP53 mutations and p53 expression in ovarian tumors. Cancer Genet Cytogenet, 105: 93-102, 1998.
41. Mowat MRA: p53 in tumor progression: life, death, and everything. Adv Cancer Res, 74: 25-48, 1998.
42. Harris CC: Structure and function of p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst, 88: 1442-1455, 1996.
43. Zeimet AG, Marth C: Why did p53 gene therapy fail in ovarian cancer? Lancet Oncol, 4: 415-422, 2003.
44. Bosari S, Viale G, Radaelli U, Bossi P, Bonoldi E, Coggi G: p53 accumulation in ovarian carcinomas and its prognostic implications. Hum Pathol, 24: 1175-1179, 1993.
45. Niwa K, Itoh M, Murase T, Morishita S, Itoh N, Mori H, Tamaya T: Alteration of p53 gene in ovarian carcinoma: clinicopathological correlation and prognostic significance. Br J Cancer, 70: 1191-1197, 1994.
46. Reles AE, Gee C, Schellschmidt I, Schmider A, Unger M, Friedmann W, Lichtenegger W, Press MF: Prognostic significance of DNA content and S-phase fraction in epithelial ovarian carcinomas analyzed by image cytometry. Gynecol Oncol, 71: 3-13, 1998.
47. Eltabbakh GH, Belinson JL, Kennedy AW, Biscotti CV, Casey G, Tubbs RR, Blumenson LE: p53 overexpression is not an independent prognostic factor for patients with primary ovarian epithelial cancer. Cancer, 80: 892-898, 1997.
48. Marx D, Meden H, Ziemek T, Lenthe T, Kuhn W, Schauer A: Expression of the p53 tumour suppressor gene as a prognostic marker in platinum-treated patients with ovarian cancer. Eur J Cancer, 34: 845-850, 1998.
49. Berker B, Dunder I, Ensari A, Cengiz SD: Prognostic value of P53 accumulation in epithelial ovarian carcinomas. Arch Gynecol Obstet, 266: 205-209, 2002.
50. Giaccia AJ, Kastan MB: The complexity of p53 modulation: emerging patterns from divergent signals. Genes Develop, 12: 2973-2983, 1998.
51. Wilson JW, Pritchard DM, Hickman JA, Potten CS: Radiation-induced p53 and p21WAF-1/CIP1 expression in the murine intestinal epithelium: apoptosis and the cell cycle arrest. Am J Pathol, 153: 899-909, 1998.
52. Matsushima H, Sasaki T, Goto T, Hosaka Y, Homma Y, Kitamura T, Kawabe K, Sakamoto A, Murakami T, Machinami R: Immunohistochemical study of p21WAF1 and p53 proteins in prostatic cancer and their prognostic significance. Hum Pathol, 29: 778-783, 1998.
53. Resnik E, Trujillo YP, Taxy JB: Long-term survival and DNA ploidy in advanced epithelial ovarian cancer. J Surg Oncol, 64: 299-303, 1997.
54. Reles A, Schmider A, Press MF, Schonborn I, Friedman W, Huber-Schumacher S, Strohmeyer T, Lichtenegger W: Immunostaining of p53 protein in ovarian carcinoma: correlation with histopathological data and clinical outcome. J Cancer Res Clin Oncol, 122: 489-494, 1996.
55. Silvestrini R, Daidone MG, Veneroni S, Benini E, Scarfone G, Zanaboni F, Villa A, Presti M, Danese S, Bolis G: The clinical predictivity of biomarkers of stage III-IV epithelial ovarian cancer in a prospective randomized treatment protocol. Cancer 82: 159-167, 1998.
56. Skirnisdottir I, Sorbe B, Karlsson M, Seidal T: Prognostic importance of DNA ploidy and p53 in early stages of epithelial ovarian carcinoma. Int J Oncol, 19: 1295-1302, 2001.
57. Weller M: Predicting response to cancer chemotherapy: the role of p53. Cell Tissue Res, 292: 435-445, 1998.